XNCR · Xencor, Inc. · Stock research

Current Thesis

Xencor is mid-transition from a royalty collector into a wholly-owned-pipeline biotech, and that pivot is what buyers are re-rating. Royalty revenue is collapsing (Q1 2026 revenue $4.5M vs $32.7M a year earlier, reported May 6, 2026) as Ultomiris royalties shrink and a royalty dispute with AstraZeneca/Alexion sits unresolved. In its place the story is XmAb819 (ENPP3 × CD3 bispecific) in clear-cell renal cell carcinoma and XmAb942 (TL1A) in ulcerative colitis. The stock ran from a $6.92 52-week low to a $17.47 close (July 17, 2026, +16.9%) on pipeline optimism, not a data print — and the actual binary, XmAb819 expansion-cohort data, does not land until ESMO on October 23–27, roughly a quarter away. That leaves a name extended near 52-week highs with no catalyst inside 30 days and a Q2 report due in early August. The clean structure is a base or a pullback-to-support reclaim, not a chase into highs.

Bullish and bearish views on Xencor, Inc.

The model's bull view on Xencor, Inc. (XNCR), in brief: First late-stage owned asset getting a stage: XmAb819 (ENPP3 × CD3) expansion-cohort data in advanced ccRCC was accepted for oral presentation at ESMO, October 23–27, 2026 (announced July 17). The bear view: The revenue engine is failing: Q1 2026 revenue $4.5M vs $32.7M YoY; the Incyte milestone did not repeat and Ultomiris royalties were reduced. Both cases follow in full.

Bull Case

• First late-stage owned asset getting a stage: XmAb819 (ENPP3 × CD3) expansion-cohort data in advanced ccRCC was accepted for oral presentation at ESMO, October 23–27, 2026 (announced July 17). Management frames it as support for a first pivotal study planned in 2027 — the concrete step the pivot narrative needs.
• TL1A optionality: XmAb942 is enrolling the global Phase 2b XENITH-UC study in ulcerative colitis. TL1A is a sought-after IBD mechanism — Merck paid ~$10.8B for Prometheus (2023) and Roche ~$7.1B for Televant (2023) — so a credible Phase 2b readout carries partnering/M&A optionality.
• Funded through the readouts: $541.8M in cash and marketable securities at March 31, 2026, guided to $380–400M by year-end, runway into mid-2028 (May 6). The pipeline can reach data without a near-term raise.
• Momentum structure intact: +16.9% to $17.47 on July 17 off a $6.92 52-week low, trading in the top decile of its range near the $18.69 high.
• Sell-side still constructive: Truist maintained Buy on July 7, 2026, with a $27 target — roughly 55% above the July 17 close even after the cut.

Bear Case

• The revenue engine is failing: Q1 2026 revenue $4.5M vs $32.7M YoY; the Incyte milestone did not repeat and Ultomiris royalties were reduced. An active Ultomiris royalty dispute with AstraZeneca/Alexion ties a chunk of value to a legal outcome.
• Heavy burn, dilution clock running: Q1 net loss $128.9M / EPS -$1.71 (includes a Zenas write-down). Cash guided down ~$150M this year; a raise becomes a live question well before mid-2028.
• No 30-day fuel: The real driver (XmAb819 data) is ~90 days out. The July 20 "moving higher" appearance was a retail gainers screen alongside crypto miners (IREN, HUT, CIFR, CLSK, APLD) and AMC — flow, not oncology-cluster confirmation.
• Target direction is down: Truist cut its PT to $27 on July 7 even while keeping Buy; estimate revisions are lower.
• Early, binary science: XmAb819 is a Phase 1 asset, and single-arm bispecific T-cell-engager data in solid tumors has a long record of CRS and efficacy disappointments. This is an unproven readout, not a de-risked one.

Setup & Price Structure

• Last reference ~$17.47 (July 17 close); 52-week range $6.92–$18.69, so price is pressed against the upper boundary near highs.
• Pre-pop consolidation shelf sat roughly $14.69–$15.72 in early July; the July 17 session gapped +16.9% through it on volume.
• The trend off the spring lows is up and the 20-week structure is rising, but the momentum leg has no near-term catalyst behind it — a MATURING advance running ahead of its data, rather than an accelerating one with a scheduled binary.
• For a fresh entry the risk/reward is poor: extended ~150% off the low, into a Q2 print, with the value-inflection event a quarter away. A reclaim of the early-July shelf as support after a pullback is the cleaner structure to buy.

Catalyst Calendar (next 30 days)

• 2026-10-23 to 2026-10-27 (beyond 30d, the real driver): XmAb819 ccRCC expansion-cohort data, oral presentation at ESMO.
• H2 2026 – 2027: XmAb942 XENITH-UC (ulcerative colitis) enrollment/interim progress — no fixed date.
• 2027 (planned): initiation of the first XmAb819 pivotal study.

Elapsed catalysts

• ~2026-08-06 (est.): Q2 2026 financial results — royalty trajectory, Ultomiris-dispute status, updated cash burn. Binary enough to warrant standing aside into the print rather than entering ahead of it. (passed 3d ago)

What Would Change Our Mind

• Bull confirmation: a decisive reclaim and hold above the $18.69 52-week high on expanding volume with oncology-immunology peers participating would flip the read to a re-accelerating theme and justify a momentum entry. A positive XmAb819 data pre-signal or a TL1A partnering headline would do the same.
• Invalidation: a weekly close below $14 loses the early-July breakout shelf and the higher-low structure built off the $6.92 low, ending the momentum leg. A resolution of the Ultomiris dispute against Xencor, or XmAb819 data slipping past ESMO, would independently break the thesis.

Correlation Notes

• Clinical-stage antibody biotech: moves with XBI biotech beta and small-cap risk appetite far more than any AI/semis theme; rate-sensitive on the funding side.
• TL1A read-through peers: Merck (post-Prometheus), Roche (Televant), plus Teva/Sanofi duvakitug — XmAb942 enters a crowded IBD field where competitive data can reprice it.
• Royalty read-through: Ultomiris (AstraZeneca/Alexion) and Monjuvi/tafasitamab (Incyte) — both declining, and the Ultomiris leg is now a legal-outcome variable.
• The July 20 gainers grouping was a retail-flow screen (crypto miners and AMC), so that day's move should be treated as noise rather than fundamental confirmation.